🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I wish the ISTH guideline panel attended this law talk by Jan Blaty clearly showing that standard half life prophylaxis is not equivalent to ultra extended half life product or Emicizumab!!

Just in time for #ASH24; our new paper from Yale Cancer Center YaleHematology group examined the Global Disparities in Characteristics & Outcomes of Leukemia Clinical Trials, led by rising 🇯🇴 star Abdulrahman Alhajahjeh, MD We need more trials in developing countries ascopubs.org/doi/10.1200/GO…

#ASH24 ASH #mmsm The future of CAR-T Constructs

Fantastic talk on results from Ziftomenib Combined with (7+3) in patients with newly diagnosed AML by Amer Zeidan MBBS,MHS ‏عامر زيدان Yale Cancer Center! It is really exciting that the targeted therapies are becoming the first line for leukemia!!

#ASH24 #mmsm ASH Nice algorithm for therapeutic anticoagulation for cancer associated VTE

Totally! #ASHKudos to ASH ☺️ for all the phenomenal sessions to advance care and thought through opportunities for building a cohesive global hematology community!! #mmsm

Its a wrap of a very exciting #ASH24 It was great meeting friends and colleagues. Enjoyed terrific science and San Diego. Wish everyone safe journey back home. Even more excited for #ASH25 as a resident!🩸ASH Belinda Avalos, MD Hematology & Oncology Women Physicians Group—HOWPG Women In Medicine® #match2025

In women with brca-associated breast cancer, prophylactic oophorectomy improves survival. Important preventative measure. ⁦Matteo Lambertini, MD PhD⁩

I have been following this with interest for over 10 years, since asked to write an editorial on the possible risk. We concluded back then there was insufficient data for any conclusion but reason for caution. This FAERS report does suggest an association pmc.ncbi.nlm.nih.gov/articles/PMC96…

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:

Never have I imagined that as a second-year fellow, I would be presenting an oral presentation at the world’s largest oncology conference, #ASCO2025! Beyond thrilled to share my research and learn from the brightest minds in the field. Grateful to my mentor, Shipra Gandhi ✨✨

As expected the FDA has today announced that it has approved Fitusiran for individuals aged 12+ with #hemophilia A or B with or without inhibitors. Commercial name is Qfitlia - they must have tried hard to find a difficult to pronounce name. tinyurl.com/mr4xmawt

So grateful for the opportunity!! Can’t wait to join the amazing UB Internal Medicine family and meet all the incredible mentors and co-residents.

Small Papers, Big Impact: A #ProgramDirectorsNote to my Yale IM Traditional Residency Program residents. Yale Internal Medicine. Five papers that changed the way I practice critical care. medicine.yale.edu/internal-medic…

If you are a scientist who is not using AI yet, this article from today's nature journal will be of great help. Whether we like it or not AI will be everywhere very soon, just like the internet.

I've been working in the cardiac ICU. The long shifts and patient deaths are tough. But the moment that hit hardest? A woman looked at me and said, "50 years. Every day, I came home to him. And now.. it'll be an empty house." I held her hand-no words could fill that silence.

Huge congratulations Toni Choueiri, MD and very well deserved!